Morusinol extracted from morus alba inhibits arterial thrombosis and modulates platelet activation for the treatment of cardiovascular disease

Jung Jin Lee, Hyun Yang, Yeong Min Yoo, Seong Su Hong, Dongho Lee, Hyun Jung Lee, Hak Ju Lee, Chang Seon Myung, Kyung Chul Choi, Eui Bae Jeung

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Morus alba (white mulberry) has been used in traditional Chinese medicine as an anti-headache, diuretic, expectorant, and anti-diabetic agent. In previous studies, extracts of Morus alba demonstrated favorable biological properties, such as antioxidant activity, suppression of lipoxygenase (LOX)-1, cytotoxicity against cancer cells, and inhibition of the invasion and migration of cancer cells. Aim: This study further evaluated the effects of morusinol, a flavonoid derived from Morus alba root bark, on platelet aggregation and thromboxane B2 (TXB2) formation in vitro and thrombus formation in vivo. Methods: The antiplatelet potential of morusinol was measured using in vitro rabbit platelet aggregation and TXB2 formation assays. Arterial thrombus formation was investigated using an in vivo ferric chloride (FeCl3)-induced thrombosis model. Results: Morusinol significantly inhibited collagen- and arachidonic acid-induced platelet aggregation and TXB2 formation in cultured platelets in a concentration-dependent manner. Thrombus formation was reduced by 32.1, 42.0, and 99.0% for collagen-induced TXB2 formation, and 8.0, 24.1, and 29.2% for arachadonic acid-induced TXB2 formation, with 5, 10, and 30 μg/mL morusinol, respectively. Moreover, oral morusinol (20 mg/kg) or aspirin (20 mg/kg) for three days significantly increased the time to occlusion in vivo by 20.3±5.0 or 6.8±2.9 min, respectively, compared with the control (1% CMC, carboxymethyl cellulose). Conclusion: Taken together, these results indicate that morusinol may significantly inhibit arterial thrombosis in vivo due to antiplatelet activity. Thus, morusinol may exert beneficial effects on transient ischemic attacks or stroke via the modulation of platelet activation.

Original languageEnglish
Pages (from-to)516-522
Number of pages7
JournalJournal of Atherosclerosis and Thrombosis
Volume19
Issue number6
DOIs
Publication statusPublished - 2012 Jul 11

Fingerprint

Morus
Platelet Activation
Platelets
Thromboxane B2
Thrombosis
Cardiovascular Diseases
Chemical activation
Platelet Aggregation
Agglomeration
Therapeutics
Collagen
Cells
Cell Migration Inhibition
Expectorants
Carboxymethylcellulose Sodium
Lipoxygenase
Transient Ischemic Attack
Chinese Traditional Medicine
Cytotoxicity
morusinol

Keywords

  • Morus alba
  • Morusinol
  • Platelet aggregation
  • Thrombus formation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine
  • Biochemistry, medical

Cite this

Morusinol extracted from morus alba inhibits arterial thrombosis and modulates platelet activation for the treatment of cardiovascular disease. / Lee, Jung Jin; Yang, Hyun; Yoo, Yeong Min; Hong, Seong Su; Lee, Dongho; Lee, Hyun Jung; Lee, Hak Ju; Myung, Chang Seon; Choi, Kyung Chul; Jeung, Eui Bae.

In: Journal of Atherosclerosis and Thrombosis, Vol. 19, No. 6, 11.07.2012, p. 516-522.

Research output: Contribution to journalArticle

Lee, Jung Jin ; Yang, Hyun ; Yoo, Yeong Min ; Hong, Seong Su ; Lee, Dongho ; Lee, Hyun Jung ; Lee, Hak Ju ; Myung, Chang Seon ; Choi, Kyung Chul ; Jeung, Eui Bae. / Morusinol extracted from morus alba inhibits arterial thrombosis and modulates platelet activation for the treatment of cardiovascular disease. In: Journal of Atherosclerosis and Thrombosis. 2012 ; Vol. 19, No. 6. pp. 516-522.
@article{da1fba8e65d34fa283f0d0d077f87a2b,
title = "Morusinol extracted from morus alba inhibits arterial thrombosis and modulates platelet activation for the treatment of cardiovascular disease",
abstract = "Morus alba (white mulberry) has been used in traditional Chinese medicine as an anti-headache, diuretic, expectorant, and anti-diabetic agent. In previous studies, extracts of Morus alba demonstrated favorable biological properties, such as antioxidant activity, suppression of lipoxygenase (LOX)-1, cytotoxicity against cancer cells, and inhibition of the invasion and migration of cancer cells. Aim: This study further evaluated the effects of morusinol, a flavonoid derived from Morus alba root bark, on platelet aggregation and thromboxane B2 (TXB2) formation in vitro and thrombus formation in vivo. Methods: The antiplatelet potential of morusinol was measured using in vitro rabbit platelet aggregation and TXB2 formation assays. Arterial thrombus formation was investigated using an in vivo ferric chloride (FeCl3)-induced thrombosis model. Results: Morusinol significantly inhibited collagen- and arachidonic acid-induced platelet aggregation and TXB2 formation in cultured platelets in a concentration-dependent manner. Thrombus formation was reduced by 32.1, 42.0, and 99.0{\%} for collagen-induced TXB2 formation, and 8.0, 24.1, and 29.2{\%} for arachadonic acid-induced TXB2 formation, with 5, 10, and 30 μg/mL morusinol, respectively. Moreover, oral morusinol (20 mg/kg) or aspirin (20 mg/kg) for three days significantly increased the time to occlusion in vivo by 20.3±5.0 or 6.8±2.9 min, respectively, compared with the control (1{\%} CMC, carboxymethyl cellulose). Conclusion: Taken together, these results indicate that morusinol may significantly inhibit arterial thrombosis in vivo due to antiplatelet activity. Thus, morusinol may exert beneficial effects on transient ischemic attacks or stroke via the modulation of platelet activation.",
keywords = "Morus alba, Morusinol, Platelet aggregation, Thrombus formation",
author = "Lee, {Jung Jin} and Hyun Yang and Yoo, {Yeong Min} and Hong, {Seong Su} and Dongho Lee and Lee, {Hyun Jung} and Lee, {Hak Ju} and Myung, {Chang Seon} and Choi, {Kyung Chul} and Jeung, {Eui Bae}",
year = "2012",
month = "7",
day = "11",
doi = "10.5551/jat.10058",
language = "English",
volume = "19",
pages = "516--522",
journal = "Journal of Atherosclerosis and Thrombosis",
issn = "1340-3478",
publisher = "Japan Atherosclerosis Society",
number = "6",

}

TY - JOUR

T1 - Morusinol extracted from morus alba inhibits arterial thrombosis and modulates platelet activation for the treatment of cardiovascular disease

AU - Lee, Jung Jin

AU - Yang, Hyun

AU - Yoo, Yeong Min

AU - Hong, Seong Su

AU - Lee, Dongho

AU - Lee, Hyun Jung

AU - Lee, Hak Ju

AU - Myung, Chang Seon

AU - Choi, Kyung Chul

AU - Jeung, Eui Bae

PY - 2012/7/11

Y1 - 2012/7/11

N2 - Morus alba (white mulberry) has been used in traditional Chinese medicine as an anti-headache, diuretic, expectorant, and anti-diabetic agent. In previous studies, extracts of Morus alba demonstrated favorable biological properties, such as antioxidant activity, suppression of lipoxygenase (LOX)-1, cytotoxicity against cancer cells, and inhibition of the invasion and migration of cancer cells. Aim: This study further evaluated the effects of morusinol, a flavonoid derived from Morus alba root bark, on platelet aggregation and thromboxane B2 (TXB2) formation in vitro and thrombus formation in vivo. Methods: The antiplatelet potential of morusinol was measured using in vitro rabbit platelet aggregation and TXB2 formation assays. Arterial thrombus formation was investigated using an in vivo ferric chloride (FeCl3)-induced thrombosis model. Results: Morusinol significantly inhibited collagen- and arachidonic acid-induced platelet aggregation and TXB2 formation in cultured platelets in a concentration-dependent manner. Thrombus formation was reduced by 32.1, 42.0, and 99.0% for collagen-induced TXB2 formation, and 8.0, 24.1, and 29.2% for arachadonic acid-induced TXB2 formation, with 5, 10, and 30 μg/mL morusinol, respectively. Moreover, oral morusinol (20 mg/kg) or aspirin (20 mg/kg) for three days significantly increased the time to occlusion in vivo by 20.3±5.0 or 6.8±2.9 min, respectively, compared with the control (1% CMC, carboxymethyl cellulose). Conclusion: Taken together, these results indicate that morusinol may significantly inhibit arterial thrombosis in vivo due to antiplatelet activity. Thus, morusinol may exert beneficial effects on transient ischemic attacks or stroke via the modulation of platelet activation.

AB - Morus alba (white mulberry) has been used in traditional Chinese medicine as an anti-headache, diuretic, expectorant, and anti-diabetic agent. In previous studies, extracts of Morus alba demonstrated favorable biological properties, such as antioxidant activity, suppression of lipoxygenase (LOX)-1, cytotoxicity against cancer cells, and inhibition of the invasion and migration of cancer cells. Aim: This study further evaluated the effects of morusinol, a flavonoid derived from Morus alba root bark, on platelet aggregation and thromboxane B2 (TXB2) formation in vitro and thrombus formation in vivo. Methods: The antiplatelet potential of morusinol was measured using in vitro rabbit platelet aggregation and TXB2 formation assays. Arterial thrombus formation was investigated using an in vivo ferric chloride (FeCl3)-induced thrombosis model. Results: Morusinol significantly inhibited collagen- and arachidonic acid-induced platelet aggregation and TXB2 formation in cultured platelets in a concentration-dependent manner. Thrombus formation was reduced by 32.1, 42.0, and 99.0% for collagen-induced TXB2 formation, and 8.0, 24.1, and 29.2% for arachadonic acid-induced TXB2 formation, with 5, 10, and 30 μg/mL morusinol, respectively. Moreover, oral morusinol (20 mg/kg) or aspirin (20 mg/kg) for three days significantly increased the time to occlusion in vivo by 20.3±5.0 or 6.8±2.9 min, respectively, compared with the control (1% CMC, carboxymethyl cellulose). Conclusion: Taken together, these results indicate that morusinol may significantly inhibit arterial thrombosis in vivo due to antiplatelet activity. Thus, morusinol may exert beneficial effects on transient ischemic attacks or stroke via the modulation of platelet activation.

KW - Morus alba

KW - Morusinol

KW - Platelet aggregation

KW - Thrombus formation

UR - http://www.scopus.com/inward/record.url?scp=84863546847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863546847&partnerID=8YFLogxK

U2 - 10.5551/jat.10058

DO - 10.5551/jat.10058

M3 - Article

C2 - 22472211

AN - SCOPUS:84863546847

VL - 19

SP - 516

EP - 522

JO - Journal of Atherosclerosis and Thrombosis

JF - Journal of Atherosclerosis and Thrombosis

SN - 1340-3478

IS - 6

ER -